Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Sage Therapeutics but lowered the price target from $13 to $8.
October 30, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities has maintained a Hold rating on Sage Therapeutics and reduced the price target from $13 to $8, indicating a less optimistic outlook.
The reduction in price target from $13 to $8 by Truist Securities suggests a negative outlook on Sage Therapeutics' stock performance. The Hold rating indicates that the analyst does not recommend buying or selling the stock, but the lowered price target reflects decreased expectations for the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100